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             Abstract 22 
Purpose: The objective of this study was to demonstrate the efficacy of iclaprim in a neutropenic 23 
rat lung infection model with methicillin-resistant Staphylococcus aureus (MRSA) entrapped in 24 
alginate beads.   25 
Methods: An inoculum of 5.25x104 colony-forming units (CFU)/ml of S. aureus strain AH1252 26 
was administered intratracheally to rats with prepared alginate bacteria suspensions.   Beginning 27 
2 hours post infection, rats received: (1) iclaprim 80 mg/kg (n=17); (2) iclaprim 60 mg/kg (n=16) 28 
or (3) vancomycin 50 mg/kg (n=24), for 3 days via subcutaneous (SC) injection every 12 hours. 29 
Twelve hours after the last treatment, rats were euthanized and lungs collected for CFU 30 
determination.  31 
 Results: Iclaprim administered at 80 mg/kg or 60 mg/kg or vancomycin 50 mg/kg SC twice a 32 
day for 3 days resulted in a 6.05 log10 CFU reduction (iclaprim 80mg/kg compared with control, 33 
p <0.0001), 5.11 log10 CFU reduction (iclaprim 60 mg/kg compared with control, p < 0.0001), 34 
and 3.42 log10 CFU reduction, respectively, from the controls (p < 0.0001). Iclaprim 80 mg/kg 35 
and 60mg/kg resulted in a 2.59 and 1.69 log10 CFU reduction, respectively, from vancomycin 36 
treated animals (80mg/kg iclaprim vs. vancomycin, p=0.0005; 60 mg/kg iclaprim vs. 37 
vancomycin, p = 0.07).  Animals receiving iclaprim, vancomycin and controls demonstrated 38 
100%, 91.7%, 48.3% survival, respectively.  39 
Conclusions: In this neutropenic rat S. aureus lung infection model, rats receiving iclaprim 40 
demonstrated a greater CFU reduction than the controls or those receiving vancomycin.  41 
Word Count: 228 42 
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Introduction 45 
 46 
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most common causes 47 
of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) [1,2].  The 48 
annual incidence rate of healthcare-related MRSA pneumonia has increased from 11.3 cases per 49 
100,000 patient-days in 2008 to 15.5 cases per 100,000 patient days in 2012 [3].  MRSA causes 50 
invasive infections, like HAP and VAP, that are associated with organ dysfunction, poor 51 
outcomes with excess morbidity and mortality and high costs to the healthcare system [4,5].    52 
Iclaprim represents a novel diaminopyrimidine, which inhibits bacterial dihydrofolate 53 
reductase (DHFR) and is active against drug-resistant pathogens [6,7].  Iclaprim exhibits potent 54 
in vitro activity against S. aureus including MRSA [6], linezolid-resistant and vancomycin-55 
resistant S. aureus [8] that cause pneumonia.  Iclaprim demonstrates rapid in vitro bactericidal 56 
activity in time-kill studies in human plasma [9]. Because of these findings, iclaprim is 57 
potentially well suited for treating patients with pneumonia caused by susceptible and multidrug-58 
resistant pathogens and the hypothesis of this study is that iclaprim would be effective and 59 
reducing colony forming units and prolonging survival among animals infected with MRSA 60 
compared to both vancomycin and controls.   61 
The present study employed an experimental model of methicillin resistant S. aureus 62 
(MRSA) pulmonary infections as previously [10].  Notably, by encapsulating the bacteria within 63 
alginate, the infection model allowed for a lower inoculum to be utilized and a biofilm type 64 
environment established within the lung. 65 
 66 
Materials and Methods 67 
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Collection of bacterial strains 68 
 S. aureus AH1252 and AW6 were provided by IHMA and were gifts from Jose Entenza, 69 
Lausanne [11]. Strain AH1252 is a thymidine kinase-deficient mutant of the MRSA isolate AW6.  70 
S. aureus ATCC 29213 was used as CLSI quality control (QC) isolate for MIC determinations.  71 
 72 
Antimicrobial Susceptibility Testing  73 
MICs were determined for iclaprim and vancomycin by broth microdilution according to 74 
CLSI criteria [12,13].  75 
 76 
Preparation of bacteria 77 
Test isolates were grown overnight on trypicase soy agar (TSA) from frozen stock 78 
cultures. After overnight incubation, colonies were resuspended in saline and adjusted to an 79 
optical density of 0.1 at 625 nm. The adjusted suspensions were further diluted in a 2% alginate 80 
buffer, which was added dropwise in a ratio of 1:5 into 50 mM CaCl2 to form alginate beads. The 81 
alginate beads were stirred during the dropwise addition and then for an additional 30 minutes to 82 
ensure that the beads were fully formed. The bacterial preparation in alginate beads allowed for 83 
the establishment of a prolonged infection due to reduced efficiency of bacterial clearance with a 84 
low inoculum input. Serial dilutions of the inoculum preparations were performed to determine 85 
inoculum size (colony forming units (CFU) per mL).  86 
 87 
Preparation of compounds  88 
Cyclophosphamide was prepared in sterile deionized water, and the mixture was vortexed 89 
and sonicated in a water bath sonicator until fully dissolved. Iclaprim was prepared by weighing 90 
! 5 
out the appropriate amount and dissolving in 30% propylene glycol vehicle. The preparation was 91 
sonicated in a water bath sonicator until dissolved. Vancomycin was prepared in sterile deionized 92 
water and vortexed to dissolve. 93 
 94 
Animal Acquisition and Acclimatization  95 
All procedures in this protocol were in compliance with the Animal Welfare Act, the 96 
Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal 97 
Welfare.  Upon receipt at NeoSome Life Sciences, Sprague Dawley male rats (Charles River 98 
Laboratories, Wilmington MA) were examined by personnel to ensure acceptable health status. 99 
Veterinary care was provided by the veterinarians and staff employed by NeoSome Life Sciences.  100 
Rats were acclimated for at least 5 days prior to testing. Rats were housed 3 per cage. 101 
Cage size met or exceeded the requirements set forth by the ILAR Guide for the Care and Use of 102 
Laboratory Animals. The animals were kept in a room maintained at 68 to 79¡F (20-26¡C) with 103 
humidity set at 30 to 70%. The room was illuminated with fluorescent lights timed to give a 12-104 
hour light, 12-hour dark cycle. Rodent diet (Purina 5001) and water were available for all rats. 105 
The feed was analyzed by the supplier detailing nutritional information and levels of specified 106 
contaminants.  107 
 108 
Pre-treatment, Inoculation Procedure, and Treatment  109 
Rats were pretreated with cyclophosphamide monohydrate to render them neutropenic. 110 
Based on literature review and previous experience with this model, rats were dosed 111 
intraperitoneally (IP) on day -4 with 100 mg/kg. On day -1 rats received a second IP dose at 75 112 
mg/kg [14, 15].  This regimen of neutropenia has been found to be effective in suppressing the 113 
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immune system of the rat for this model.  114 
Rats were infected with prepared alginate bacteria suspensions while under isoflurane 115 
anesthesia (4.5% isoflurane; 2.5 L/min O2). Utilizing a sterile 20G, 3-inch stainless steel feeding 116 
needle, a 0.5 mL volume was delivered via intratracheal inoculation (IT). Holding the 117 
anesthetized rat in a vertical plane, the feeding needle was advanced into the trachea and the 118 
volume was instilled. The rat was returned to its cage and allowed to recover from the anesthesia.  119 
Beginning at 2 hours post infection, rats were randomized to treatment with iclaprim, 120 
vancomycin or 30% propylene glycol vehicle (controls).  Test articles were prepared fresh for 121 
each day of dosing and formulated material was stored at 4oC, protected from light between the 122 
two daily doses. Animals were dosed by body weight in a volume of 5 mL/kg subcutaneously. 123 
These series of studies were designed to evaluate efficacy in a step-wise fashion. An initial dose 124 
of iclaprim 80 mg/kg per dose was selected based on a previous studies in animal models of 125 
infection, including a model of bacteremia and abscess (unpublished data).  Two different 126 
dosages of iclaprim (80 mg/kg and 60 mg/kg) were used to show comparability with other 127 
iclaprim animal infection models and to establish which dose works best in this alginate bead 128 
model.  Vancomycin was selected as a comparator based on activity observed in other rats 129 
models with difficult to treat infections [16, 17] and given its clinical use for staphylococcal 130 
infection.  Non-treatment infection control animals received vehicle (30% propylene glycol). 131 
 132 
Sample processing  133 
No samples were collected before euthanasia.  At 74 hours post infection, rats were euthanized 134 
by CO2 inhalation. One group of rats was euthanized at 2 hours post-infection to determine 135 
bioload at initiation of therapy. Rat lungs were aseptically removed, weighed, and homogenized 136 
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to a uniform consistency using a Polytron PT2100 with a 12 mm dispersing homogenizer 137 
(Bohemia, NY). The homogenized samples were serially diluted (10 fold dilutions) in sterile 0.9% 138 
saline and plated on TSA plates. The plates were incubated overnight at 37oC and CFUs were 139 
enumerated by counting the plated colonies, adjusting for dilution factor and lung weight to 140 
obtain CFUs/ gram of lung.  The recovered bacteria were MRSA.  While not conducted routinely, 141 
spot checking of bacteria recovered from the lung homogenates were also plated on oxacillin 142 
containing media with the same results (same CFU count).  This suggests the recovered 143 
organisms were MRSA.  Some minor contamination is expected with this model, though it is at 144 
low levels and most often a fungus or mold, both of these are easily identified and can be 145 
discounted when quantifying the CFUs.  This model has been previously validated and 146 
confirmed that the bacterial input and recovery are consistent.  Additionally, the rats are 147 
maintained in a clean environment and are received from the vendor in good health (with health 148 
reports provided) which significantly limits the potential for contamination. 149 
 150 
Statistical analyses 151 
Group sizes of nine animals each were determined to be adequate through power analysis 152 
assuming 80% probablility and a standard deviation 0.5 log10 CFU. These numbers allowed for 153 
the detection of 0.7 log10 CFUs between groups. The average, standard deviation, and standard 154 
error of the mean (SEM) CFUs were calculated for each group of animals. One-way analysis of 155 
variance (1way ANOVA) with multiple comparison post test (Bonferroni) was used to compare 156 
the means of CFUs/ gram of lung between experimental groups at two time points, 2 and 74 157 
hours post-infection. Specifically, comparisons were made of the 74 hour post-infection CFU / 158 
gram of lung and survival > 60 hours  between both iclaprim dosing regimens (80 mg/kg and 60 159 
! 8 
mg/kg) compared to infection controls (vehicle alone), vancomycin compared to infection 160 
controls, and both iclaprim dosing regimens compared to vancomycin. A p-value 0.05 was 161 
considered to be significant. 162 
 163 
Results 164 
$JDLQVWLVRODWHV$:DQG$+0,&YDOXHVIRULFODSULPZHUHȝJPOIRUERWK165 
DQGȝJPODQGȝJPOIRUYDncomycin, respectively. 166 
Table 1 and Figure 1 show the CFU reduction and mortality by treatment.  Rats infected 167 
with S. aureus AH1252 demonstrated an average bioload of 3.53 log10 CFU per gram of lung at 168 
the 2 hour initiation of therapy. Besides MRSA, no other microorganisms were identified in the 169 
lungs of any animals.  Untreated infected rat lungs demonstrated an average bioload of 8.70 log10 170 
CFU/gram of lung at 74 hours post infection, a 5.17 log10 CFU increase in bioburden over 72 171 
hours. Iclaprim administered at 80 mg/kg subcutaneously twice a day for 3 days resulted in a 172 
6.05 log10 CFU reduction from the 74 hour infection controls (p <0.0001). Additionally, a 0.88 173 
log10 CFU reduction was observed for iclaprim dosed at 80 mg/kg when compared with the 174 
bioload at initiation of therapy. This reduction suggests bacterial killing is occurring which was 175 
not observed with vancomycin under these study conditions. Iclaprim administered 60 mg/kg 176 
subcutaneously twice per day demonstrated activity in the rat lung infection model with a 5.11 177 
log10 CFU reduction from the 74 hour infection controls (p < 0.0001).  In comparison, 178 
vancomycin administered at 50 mg/kg subcutaneously twice a day for 3 days demonstrated a 179 
5.28 log10 CFU/gram of lung bioburden, a 3.42 log10 CFU reduction from the 74 hour infection 180 
controls (p < 0.0001). Iclaprim 80 mg/kg and 60mg/kg resulted in a 2.59 and 1.69 log10 CFU 181 
reduction, respectively, from vancomycin treated animals (80mg/kg iclaprim vs. vancomycin, 182 
! 9 
p=0.0005; 60 mg/kg iclaprim vs. vancomycin, p = 0.07).   183 
Control animals infected with S. aureus had 48.3% (14 of 29) survival.  In contrast, 184 
animals receiving iclaprim had 100% survival (33 out of 33), while vancomycin-treated animals 185 
had 91.7% (22 out of 24) survival (both iclaprim and vancomycin treated animals showed 186 
increased survival compared to control animals, chi-square test, p < 0.01).  187 
 188 
Discussion  189 
This report demonstrates that iclaprim produces significant and sustained efficacy in the 190 
current pulmonary model of lung infection due to MRSA, compared with vancomycin.  The data 191 
support the potential use of iclaprim in the treatment of staphylococcal pulmonary infections.  192 
The combination of the alginate encapsulated bacteria and ensuing biofilm formation established 193 
a bacterial growth environment that was difficult to treat and eradicate, providing a useful model 194 
to test the ability of antibiotics to treat challenging pulmonary bacterial infections. Patients with 195 
CF can have S. aureus pulmonary infections.  Therefore, it is important that antibiotics aimed to 196 
treat such infections be able to distribute and concentrate in the lung compartments. 197 
A Phase 1 study investigated the tissue distribution of a single IV dose of iclaprim in 198 
relevant lung compartments [18].  Iclaprim concentrations found in epithelial ling fluid (ELF) 199 
and alveolar macrophages (AM) were up to 20- and 40-fold higher, respectively, than in plasma.  200 
In addition, iclaprim concentrations in plasma, ELF and AM after a single IV dose of 1.6 mg/kg 201 
exceeded iclaprim MICs for penicillin- susceptible S. pneumoniae (MIC
90 0.06 mg/L) and 202 
methicillin-resistant S. aureus (MIC90 0.12 mg/L)
 for up to 7 hours; mean iclaprim 203 
concentrations in ELF exceeded the iclaprim MICs observed for S. pneumoniae with 204 
intermediate penicillin resistance (MIC90 2 mg/L) and full resistance (MIC90 4 mg/L) for up to 7 205 
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and 4 hours, respectively, after a single dose. 206 
S. aureus AH1252 strain, which is deficient in thymidine kinase, was used in this study 207 
because it has been reported that the uptake of exogenous thymidine and it conversion into 208 
thymidylate by thymidine kinase in certain bacteria, including S. aureus, antagonize with the 209 
antimicrobial activity of the DHFR inhibitor trimethoprim in vitro [19]. It also is known that the 210 
VHUXPRIURGHQWVFRQWDLQVODUJHFRQFHQWUDWLRQVRIWK\PLGLQHFRPSDUHGWRKXPDQVHUXPLH211 
DQGȝg/ml, respectively [19]. This is the most plausible reason to explain why testing 212 
trimethoprim or trimethoprim-sulfamethoxazole (TMP-SMX) can sometimes be ineffective in 213 
staphylococcal infection models in rodents [12,17].  A previous study by Entenza et al [11] 214 
described the use of S. aureus thymidine kinase-deficient mutants (unable to utilize exogenous 215 
thymidine) in an in vitro fibrin clot model employing iclaprim in the presence of rat and human 216 
clots. The utility of the thymidine kinase mutants was evident, as thymidine no longer 217 
antagonized the action of iclaprim in the rat. Thus, iclaprim demonstrated high efficacy in rat 218 
(high thymidine) containing clots generated in the presence of these thymidine kinase deficient S. 219 
aureus strains, but not, as expected, with the thymidine kinase producing wild type strains [11]. 220 
There are limitations to this study.  First, only two doses and two timepoints with a single 221 
inoculum challenge were used in this study.  No pharmacokinetics (i.e., no blood or lung levels 222 
of iclaprim or vancomycin) were performed because the two doses were based on previous 223 
studies of iclaprim in animal infection models and mimicking exposures in patients (unpublished 224 
data). Second, the starting inoculum in rodents was low compared to other models because by 225 
encapsulating bacteria within alginate, the infection model allowed for a lower inoculum to be 226 
utilized and a biofilm type environment established within the lung.  Although this may lower 227 
the therapeutic hurdle, all groups, control, iclaprim and vancomycin treated rats, received the 228 
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same starting inoculum.  Furthermore, this starting inoculum is consistent with other published 229 
alginate bead pneumonia models [10]. Third, no microbiological samples or counts were 230 
collected or measured before euthanasia of the animals therefore the initial challenge might not 231 
be the same in the lungs.  232 
This current pulmonary model of lung infection due to MRSA is consistent with results 233 
from a Phase 2 study showing activity of iclaprim in patients with nosocomial pneumonia.  In the 234 
Phase 2 study, the clinical cure rates of two iclaprim dosages were compared with that of 235 
vancomycin in the treatment of patients with nosocomial pneumonia suspected or confirmed to 236 
be caused by Gram-positive pathogens; this study showed iclaprim and vancomycin to have 237 
comparable clinical cure rates and safety profiles in these patients [20].  The cure rates in the 238 
intent-to-treat population were 73.9% (17 of 23), 62.5% (15 of 24), and 52.2% (12 of 23) at the 239 
post-treatment test of cure visit in the iclaprim 0.8 mg/kg intravenous (IV) q12h, iclaprim 1.2 240 
mg/kg IV q8h, and vancomycin 1 g IV q12h groups, respectively (iclaprim q12h versus 241 
vancomycin p = 0.13; and iclaprim q8h versus vancomycin p = 0.47). The death rates within 28 242 
days of the start of treatment were 8.7% (2 of 23), 12.5% (3 of 24), and 21.7% (5 of 23) for the 243 
iclaprim q12h, iclaprim q8h, and vancomycin groups, respectively (no statistically significant 244 
differences).   245 
Collectively, the current in vivo study, and previous Phase 1 and 2 clinical studies support 246 
the use of iclaprim development as a potential treatment for S. aureus pneumonia, including 247 
possibly among patients with biofilm mediated infection, as seen for example in CF. 248 
 249 
 250 
 251 
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Table 1  Colony forming unit change at 74 hours and survival at >60 hours by treatment 252 
groups 253 
 254 
Abbreviations: NA, not applicable; SC, subcutanoues; BID, twice a day; CFU, colony forming 255 
unit; hr, hour 256 
 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
 268 
Group 
(number of 
rats) 
Dose 
(mg/kg/dose) 
Route / 
regimen 
Survival > 
60h 
Log10 
Change in 
CFU at 74 
hr. 
P-value 
compared to 
control / 
vancomycin 
Control 
(n=22) 
vehicle SC/BID 48.3% NA NA 
Iclaprim 
(n=16) 
80 SC/BID 100% -6.05 <0.0001 / 
0.0005 
Iclaprim 
(n=16) 
60 SC/BID 100% -5.11 <0.0001 / 
0.0732 
Vancomycin 
(n=24) 
50 SC/BID 91.7% -3.42 <0.0001 / 
NA 
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Figure Legend 269 
Figure 1 The x and o indicate the geometric mean and individual rat log10 CFU/gram of lung, 270 
respectively.  The box plot and whiskers indicate 25/50/75th percentile and <25/>75th percentile, 271 
respectively. 272 
 273 
 274 
Figure 1  Average log10 colony forming unit / gram of lung tissue at 74 hours among 275 
treatment groups 276 
 277 
 278 
 279 
Abbreviations: CFU, colony forming unit; SC, subcutaneous; BID, twice a day 280 
 281 
 282 
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